Jamaica Boosting Its Energy Industry
9.8.2021 21:30:00 EEST | Business Wire | Press release
The Caribbean’s leader in renewable energy, Jamaica, is making significant strides in boosting the diversification of its energy sector, as the government looks to implement the island’s ambitious Integrated Resource Plan (IRP).
The initiative has set a goal of adding around 1,600 megawatts (MW) of generation capacity over the next 20 years to expand the island’s energy resources. The aim is to facilitate reduced energy prices, and decrease vulnerability of the energy sector to external shocks such as oil prices. The IRP creates business opportunities in the form of requests for proposals (RFPs) that seek investors to fulfill the demand for more energy generation.
The IRP’s targets include 1260 MW of wind and solar, 330 MW of liquid natural gas (LNG), and 74 MW of hydro, biomass or waste energy by the year 2037. JAMPRO, Jamaica’s investment promotions agency, is tasked with securing the local and foreign investment that will drive the plan’s success, and the achievement of these targets.
The island is well on its way. Jamaica wants to have 33 per cent of electricity generation from renewables by 2030, and there are already impressive renewable energy projects on the island that are proving to be a strong foundation for the country’s energy resource plan. The 20-megawatt (MW) Content Solar Ltd. solar energy electricity generation plant owned by WRB Energy Company in Clarendon is one such example. In Westmoreland, the largest photovoltaic power plant in Jamaica, the 51 MWp (megawatts-peak) Paradise Park solar farm, is one of the island’s cheapest producers of energy.
There is also the Wigton Windfarm in Rose Hill, Manchester, which is the largest facility of its kind in the Caribbean with a 20.7 MW plant and an 18 MW extension facility. Jamaica’s energy provider, the Jamaica Public Service (JPS)’s Munro Wind Farm has a 3 MW capacity, while Blue Mountain Renewable (BMR) Jamaica Wind generates 34 MW. In St. Elizabeth, the JPS utility company operates a 7.2 MW hydro-electric plant in Maggoty.
Regarding these projects, Don Gittens, JAMPRO’s Manager of Logistics, Energy, and Infrastructure, stated “Current renewable energy projects represent approximately 14 per cent of energy generation in Jamaica, but our target is 50 per cent. There is therefore a significant opportunity because we have that gap between 14 per cent and 50 per cent that we intend to fill with additional renewable energy investments.”
Jamaica is currently seeking to procure 320 MW of wind and solar, 120 MW of LNG and 74 MW of hydro, biomass or waste energy for this year. Gittens elaborated, “That is the opportunity that exists right now for investors, so, these are very exciting times.”
Interest high in Jamaica’s energy sector
According to JAMPRO, there is serious interest in Jamaica’s energy sector. The Agency is entertaining several local and international investors who are interested in partaking in the RFP that is to come with the aforementioned energy generation opportunities.
This interest was maintained by JAMPRO through the pandemic, as the organisation chose to intensify its marketing activities. The company increased its digital outreach and direct engagements with sector leaders and business executives locally and internationally.
Diane Edwards, President of JAMPRO, said, “While there was a feeling of uncertainty, especially at the beginning of the pandemic, we knew that we had to continue to nurture our relationships and the renewable energy opportunity in Jamaica, and increase our marketing activities. COVID-19 re-emphasised the fact that sectors like logistics, energy, and agriculture must be major priorities, so the Jamaican government really used this time to identify the areas that needed even more focus as we continue Jamaica’s development.”
Sector development initiatives have continued, and JAMPRO has partnered with entities like New Energy Events and the REA - The Association for Renewable Energy & Clean Technology in the UK to continue its global promotion of the energy industry. Jamaica has also begun work on the development of an electronic vehicle charging network, confirming the country’s commitment to alternative energy sources.
“This is a very exciting time within the local and global energy sector as everything is moving towards renewable energy,” Gittens enthused. “Once the RFPs are ready, we are confident there will be a lot of investment coming through.”
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce.
For more information on JAMPRO, please visit https://dobusinessjamaica.com/.
Follow us on:
Twitter
Facebook
Instagram
LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210809005015/en/
Contact information
Integrated Marketing Communications
Tamica Parchment
tparchment@jamprocorp.com
Tele: 876-978-7755
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
